AMG 151 (ARRY‐403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes

  title={AMG 151 (ARRY‐403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes},
  author={L. Katz and N. Manamley and W. J. Snyder and M. Dodds and N. Agafonova and J. Sierra-Johnson and M. Cruz and P. Kaur and S. Mudaliar and P. Raskin and R. Kewalramani and A. Pellacani},
  • L. Katz, N. Manamley, +9 authors A. Pellacani
  • Published 2016
  • Medicine
  • Diabetes
  • Phase I studies have shown that AMG 151 activates glucokinase, a key enzyme in glucose homeostasis. The present randomized, placebo‐controlled phase IIa study evaluated the dose–effect relationship of the glucokinase activator AMG 151 relative to placebo on fasting plasma glucose (FPG) in 236 patients (33–35 patients per arm) with type 2 diabetes treated with metformin. Patients received oral AMG 151 at 50, 100 or 200 mg twice daily, AMG 151 at 100, 200 or 400 mg once daily or matching placebo… CONTINUE READING
    14 Citations
    New hope for glucokinase activators in type 2 diabetes?
    • A. Scheen
    • Medicine
    • The lancet. Diabetes & endocrinology
    • 2018
    • 5
    • PDF
    Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
    • 3
    • Highly Influenced
    The potential role of glucokinase activator SHP289‐04 in anti‐diabetes and hepatic protection
    • 7
    • Highly Influenced


    Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
    • 129
    • Highly Influential
    • PDF
    GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
    • 66
    • Highly Influential
    Dose‐ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
    • 45
    • Highly Influential
    Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility.
    • 13
    Combination therapy of ARRY-403 with metformin, sitagliptin or pioglitazone results in additive glucose lowering in female ZDF rats
    • Presented at: Keystone Symposium, Banff,
    • 2009